EDSA stock news · Edesa Biotech
Get alerts for EDSA
Follow Edesa Biotech (EDSA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for EDSA12 health care stocks changed a lot after the market closed on Tuesday.
NeutralEdesa Biotech shares rose 11.7%, but the report gives no new company results or business news. The share move alone does not change its business outlook.
Edesa Biotech got the green light from the FDA to start a Phase 2 study for EB06 in vitiligo.
Good for EDSAEdesa received FDA clearance to expand its EB06 vitiligo study into the United States. This moves the study forward, though the drug's safety and benefit remain unproven.
12 health care companies saw big changes in their stock prices after the market closed on Thursday.
NeutralThe article reports that Edesa Biotech shares rose 8% after hours. It gives no business reason or company update, so the report does not change the company's outlook.
12 health care stocks changed a lot in prices after the market closed on Thursday.
NeutralEdesa Biotech shares rose about 6% to $4.24 after hours, but the article reports no business update or reason for the move. It does not change the company's outlook.
Edesa Biotech, Inc. announces the establishment of a significant definitive agreement (EDSA).
NeutralEdesa Biotech, Inc. has filed a Form 8-K indicating its entry into a material definitive agreement, which is likely to create new business opportunities and enhance investor confidence in the company's future prospects.
Edesa Biotech shares plummet following announcement of $25 million public offering.
NeutralEdesa Biotech's stock has experienced a sharp decline due to the announcement of a $25 million public offering, which has raised concerns about shareholder dilution. This capital raise follows a recent earnings release and indicates potential challenges for the company's stock performance in the near term.